Stock listing
Munich:PHPN Galectin Therapeutics Inc. Aktie
German listing (Munich) of Galectin Therapeutics Inc. · home listing NASDAQ:GALT
Follow Galectin Therapeutics Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:GALT
$2.69 USD -0.29 (-9.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GALT
- Day range
- $2.67 – $2.93 USDNov 20, 2026
- Volume
- 257,651 sharesNov 20, 2026
- Market cap
- $271.4M USDAt the close on Nov 20, 2026 · price × 100.9M shares outstanding
- 52-week range
- $2.03 – $7.13 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $942,183 USDMedian day 227,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GALT · Home | $2.69 USD | -0.29 (-9.7%) | 257,651 | $2.80 | $2.93 | $2.67 | $2.98 | Close on Nov 20, 2026 |
| Frankfurt:PHPN | €2.58 EUR | +0.12 (+4.9%) | — | €2.62 | €2.62 | €2.58 | €2.46 | Close on Nov 18, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GALT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.69 | -0.29 | -9.7% | $2.80 | $2.93 | $2.67 | 257,651 | |
| $2.98 | +0.07 | +2.4% | $2.94 | $3.00 | $2.822 | 233,788 | |
| $2.91 | -0.11 | -3.6% | $3.11 | $3.20 | $2.825 | 262,804 | |
| $3.02 | -0.03 | -1.0% | $3.11 | $3.21 | $2.93 | 231,993 | |
| $3.05 | -0.09 | -2.9% | $3.16 | $3.31 | $2.94 | 181,586 | |
| $3.14 | -0.15 | -4.6% | $3.28 | $3.534 | $3.07 | 226,410 | |
| $3.29 | -0.09 | -2.7% | $3.38 | $3.41 | $3.29 | 77,977 | |
| $3.38 | -0.08 | -2.3% | $3.44 | $3.52 | $3.30 | 167,705 | |
| $3.46 | +0.32 | +10.2% | $3.15 | $3.49 | $3.04 | 241,210 | |
| $3.14 | +0.155 | +5.2% | $3.01 | $3.18 | $2.90 | 223,428 | |
| $2.985 | -0.485 | -14.0% | $3.50 | $3.50 | $2.905 | 396,552 | |
| $3.47 | +0.12 | +3.6% | $3.47 | $3.59 | $3.387 | 217,254 | |
| $3.35 | +0.02 | +0.6% | $3.33 | $3.50 | $3.33 | 118,233 | |
| $3.33 | +0.01 | +0.3% | $3.35 | $3.43 | $3.295 | 117,155 | |
| $3.32 | -0.20 | -5.7% | $3.52 | $3.54 | $3.27 | 174,744 | |
| $3.52 | -0.02 | -0.6% | $3.61 | $3.70 | $3.448 | 263,857 | |
| $3.54 | +0.16 | +4.7% | $3.37 | $3.56 | $3.27 | 141,090 | |
| $3.38 | +0.19 | +6.0% | $3.21 | $3.44 | $3.13 | 204,733 | |
| $3.19 | 0.00 | 0.0% | $3.20 | $3.255 | $3.11 | 164,390 | |
| $3.19 | -0.19 | -5.6% | $3.37 | $3.37 | $3.16 | 195,180 | |
| $3.38 | +0.01 | +0.3% | $3.34 | $3.50 | $3.27 | 161,500 | |
| $3.37 | -0.06 | -1.7% | $3.46 | $3.51 | $3.19 | 295,700 | |
| $3.43 | -0.07 | -2.0% | $3.51 | $3.62 | $3.41 | 200,200 | |
| $3.50 | -0.12 | -3.3% | $3.60 | $3.73 | $3.47 | 177,300 | |
| $3.62 | -0.09 | -2.4% | $3.71 | $3.81 | $3.61 | 169,400 | |
| $3.71 | +0.07 | +1.9% | $3.68 | $3.84 | $3.66 | 119,200 | |
| $3.64 | -0.05 | -1.4% | $3.66 | $3.86 | $3.61 | 409,000 | |
| $3.69 | -0.18 | -4.7% | $3.84 | $3.86 | $3.67 | 184,400 | |
| $3.87 | -0.07 | -1.8% | $3.92 | $4.01 | $3.84 | 99,700 | |
| $3.94 | +0.30 | +8.2% | $3.64 | $3.97 | $3.64 | 156,400 | |
| $3.64 | +0.02 | +0.6% | $3.62 | $3.69 | $3.51 | 270,800 | |
| $3.62 | -0.14 | -3.7% | $3.74 | $3.86 | $3.59 | 176,000 | |
| $3.76 | +0.03 | +0.8% | $3.75 | $3.79 | $3.57 | 277,900 | |
| $3.73 | -0.17 | -4.4% | $3.84 | $3.90 | $3.64 | 280,700 | |
| $3.90 | +0.14 | +3.7% | $3.82 | $3.94 | $3.75 | 220,100 | |
| $3.76 | -0.12 | -3.1% | $3.87 | $4.06 | $3.68 | 327,400 | |
| $3.88 | -0.03 | -0.8% | $3.90 | $4.05 | $3.82 | 198,100 | |
| $3.91 | -0.02 | -0.5% | $3.94 | $4.00 | $3.90 | 174,200 | |
| $3.93 | +0.03 | +0.8% | $3.86 | $3.99 | $3.80 | 168,800 | |
| $3.90 | -0.06 | -1.5% | $3.93 | $3.99 | $3.86 | 124,600 | |
| $3.96 | -0.09 | -2.2% | $4.00 | $4.04 | $3.78 | 153,300 | |
| $4.05 | -0.09 | -2.2% | $4.12 | $4.15 | $4.00 | 174,000 | |
| $4.14 | +0.18 | +4.5% | $4.05 | $4.24 | $4.05 | 258,000 | |
| $3.96 | +0.07 | +1.8% | $3.91 | $4.02 | $3.85 | 258,400 | |
| $3.89 | +0.18 | +4.9% | $3.71 | $3.92 | $3.68 | 1,065,800 | |
| $3.71 | +0.03 | +0.8% | $3.73 | $3.79 | $3.69 | 171,100 | |
| $3.68 | -0.05 | -1.3% | $3.71 | $3.80 | $3.61 | 274,000 | |
| $3.73 | -0.11 | -2.9% | $3.82 | $3.83 | $3.58 | 323,100 | |
| $3.84 | -0.07 | -1.8% | $3.95 | $4.09 | $3.82 | 337,900 | |
| $3.91 | +0.01 | +0.3% | $3.92 | $4.01 | $3.84 | 243,600 | |
| $3.90 | -0.15 | -3.7% | $4.00 | $4.05 | $3.84 | 253,000 | |
| $4.05 | -0.09 | -2.2% | $4.13 | $4.34 | $4.04 | 515,600 | |
| $4.14 | -0.47 | -10.2% | $4.60 | $4.65 | $4.10 | 393,300 | |
| $4.61 | +0.26 | +6.0% | $4.33 | $4.72 | $4.33 | 473,300 | |
| $4.35 | -0.13 | -2.9% | $4.50 | $4.60 | $4.22 | 244,100 | |
| $4.48 | +0.31 | +7.4% | $4.19 | $4.53 | $4.19 | 460,400 | |
| $4.17 | +0.22 | +5.6% | $3.91 | $4.39 | $3.91 | 479,500 | |
| $3.95 | -0.07 | -1.7% | $4.02 | $4.05 | $3.91 | 229,700 | |
| $4.02 | -0.12 | -2.9% | $4.14 | $4.20 | $3.95 | 271,100 | |
| $4.14 | -0.01 | -0.2% | $4.15 | $4.45 | $4.04 | 345,200 | |
| $4.15 | +0.16 | +4.0% | $3.95 | $4.21 | $3.92 | 291,100 | |
| $3.99 | +0.11 | +2.8% | $4.07 | $4.19 | $3.85 | 194,700 | |
| $3.88 | +0.20 | +5.4% | $3.68 | $3.97 | $3.58 | 227,600 | |
| $3.68 | +0.11 | +3.1% | $3.62 | $3.74 | $3.59 | 174,900 | |
| $3.57 | -0.10 | -2.7% | $3.67 | $3.75 | $3.44 | 313,000 |
Splits
1 split · NASDAQ:GALT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-6 | Consolidation |
- Ticker
- Munich:PHPN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 51 slides
Latest news
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
Nov 16, 2026
Closed $3.02 (-1.0%) on Nov 16, 2026
Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026
Nov 5, 2026
Closed $2.99 (-14.0%) on Nov 5, 2026
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
Oct 6, 2026
Closed $3.76 (+0.8%) on Oct 6, 2026
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026
Closed $3.90 (-3.7%) on Sep 10, 2026
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Aug 14, 2026
Closed $3.44 (-2.5%) on Aug 14, 2026
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Aug 4, 2026
Closed $2.99 (-1.3%) on Aug 4, 2026
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Jun 23, 2026
Closed $3.12 (+11.4%) on Jun 23, 2026
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
May 27, 2026
Closed $2.70 (-3.2%) on May 27, 2026
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
May 15, 2026
Closed $2.17 (-7.7%) on May 15, 2026
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
May 11, 2026
Closed $2.21 (+5.2%) on May 11, 2026
Galectin Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 116 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 59 decks · latest July 2026
Where Galectin Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GALT · Home listing | NASDAQ | United States | USD |
| gettex:PHPN | gettex | Germany | EUR |
| LS Exchange:A1JV3R | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1JV3R | Lang & Schwarz | Germany | EUR |
| BOATS:GALT | BOATS | United States | USD |
| Dusseldorf:PHPN | Dusseldorf | Germany | EUR |
| Frankfurt:PHPN | Frankfurt | Germany | EUR |
| Munich:PHPN · This page | Munich | Germany | EUR |
| Stuttgart:PHPN | Stuttgart | Germany | EUR |
| Tradegate:PHPN | Tradegate | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $293.0M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.20
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| AP Biosciences, Inc. · TPEX:6945 | US$282.2M | US$215.6M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Fulcrum Therapeutics, Inc. · NASDAQ:FULC | US$281.8M | −US$17.87M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.42 |
| Circio Holding ASA · OSL:CRNA | US$281.1M | US$225.9M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | n/a |
| Relmada Therapeutics, Inc. · NASDAQ:RLMD | US$279.5M | US$77.42M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.57 |
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.4M | US$182.7M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Agenus Inc. · NASDAQ:AGEN | US$270.1M | US$218.3M | 9.2× | 1.6× | 4.0× | n/a | 22.0% | n/a | 1.80 |
| AgomAb Therapeutics NV · NASDAQ:AGMB | US$268.4M | −US$6.88M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.29 |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Median of the others | US$273.8M | US$145.2M | 9.2× | 234× | 4.0× | 2.0× | 22.0% | 0.0× | 1.46 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.26 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Joel Lewis | Chief Executive Officer (CEO) and President |
| Jack W. Callicutt | Chief Financial Officer |
| Andrew Volosov | Vice President, Clinical Pharmacology and Pharmacokinetics |
| Sharisse Brutto | Vice President, Project Management |
| Jim Wilkins | Head of CMC and Pharmaceutical Development |
| Khurram Jamil | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Richard E. Uihlein | Chairman of the Board |
| Benjamin S. Carson | Independent Director |
| Elissa J. Schwartz | Independent Director |
| Gilbert F. Amelio | Independent Director |
| Gilbert S. Omenn | Independent Director |
| Henry Brem | Independent Director |
| Kary Eldred | Independent Director |
| Kevin D. Freeman | Vice Chairman of the Board |
| Richard A. Zordani | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −1.0% |
| Q2 2026 | Aug 14, 2026 · Before open | −2.5% |
| Q1 2026 | May 15, 2026 · Before open | −7.7% |
| Q4 2025 | Mar 26, 2026 | −8.5% |
| Q3 2025 | Nov 14, 2025 · Before open | −0.4% |
| Q2 2025 | Aug 14, 2025 · Before open | +2.5% |
| Q1 2025 | May 15, 2025 · Before open | +1.5% |
| Q4 2024 | Mar 27, 2025 · Before open | +2.4% |
| Q3 2024 | Nov 14, 2024 · Before open | −5.2% |
| Q2 2024 | Aug 13, 2024 · Before open | +6.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | +7.8% |
| Q4 2023 | Mar 29, 2024 · Before open | +2.1% |
| Q3 2023 | Nov 13, 2023 · Before open | −7.1% |
| Q2 2023 | Aug 14, 2023 · Before open | 0.0% |
| Q1 2023 | May 15, 2023 · Before open | −3.0% |
| Q4 2022 | Mar 30, 2023 · Before open | +5.3% |
| Q3 2022 | Nov 14, 2022 · Before open | +5.6% |
| Q2 2022 | Aug 15, 2022 · Before open | +5.3% |
| Q1 2022 | May 16, 2022 · Before open | −7.3% |
| Q4 2021 | Mar 31, 2022 · Before open | −5.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 51 slides | July 2026 |
| Technical Presentation (March 2026) | Technical | 33 slides | Mar 10, 2026 |
| Investor Presentation (November 2025) | Investor deck | 54 slides | Nov 10, 2025 |
| Investor Presentation (September 2025) | Investor deck | 40 slides | Sep 8, 2025 |
| Technical Presentation (June 2025) | Technical | 26 slides | Jun 16, 2025 |
| Investor Presentation (May 2025) | Investor deck | 38 slides | May 12, 2025 |
| Investor Presentation (March 2025) | Investor deck | 33 slides | Mar 5, 2025 |
| Investor Presentation (January 2025) | Investor deck | 31 slides | Jan 13, 2025 |
| Investor Presentation (November 2024) | Investor deck | 24 slides | Nov 14, 2024 |
| Investor Presentation (September 2024) | Investor deck | 23 slides | Sep 9, 2024 |
Show 50 decks
This page holds 50 of 59 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Unsecured, convertible line of credit Announced: convertible Buyers: Richard E. Uihlein (Chairman; provides a new $10 million unsecured, convertible line of credit) Insiders: Line of credit provided by the company's chairman, Richard E. Uihlein Use of proceeds: Together with cash, to fund currently expected expenditures through at least March 2027 | Dec 19, 2025 |
| Convertible promissory notes under an unsecured line of credit, with stock purchase warrants Announced: up to 200,000 stock purchase warrants (20,000 per $1 million of borrowings), exercise… Buyers: Richard E. Uihlein (Provides the new $10 million unsecured convertible line of credit) Insiders: The credit line is provided by Richard E. Uihlein, Chairman of the Board and largest individual stockholder Use of proceeds: To cover projected expenditures through June 2026 | Jul 9, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 37.0K | 33.0K | 32.0K | 41.0K | 36.0K | 35.0K | 1.00K | 1.00K | 7.00K | |
| Gross profit | -37.0K | -33.0K | -32.0K | -41.0K | -36.0K | -35.0K | -1.00K | -1.00K | -7.00K | |
| Research and development | 14.3M | 36.6M | 32.1M | 31.7M | 23.8M | 18.0M | 7.47M | 6.47M | 11.7M | 15.3M |
| Selling, general and administrative | 5.79M | 5.86M | 5.94M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M |
| Operating income | -20.1M | -42.4M | -38.1M | -38.4M | -30.2M | -23.4M | -13.4M | -13.6M | -16.2M | -21.5M |
| Depreciation and amortization | 53.0K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.00K | 7.00K |
| EBITDA | -20.0M | -42.4M | -38.1M | -38.4M | -30.2M | -23.4M | -13.4M | -13.6M | -16.2M | -21.5M |
| Interest expense | 7.33M | 5.54M | 2.79M | 1.03M | 489.0K | 87.0K | 87.0K | 336.0K | 12.0K | 0 |
| Income before tax | -30.8M | -47.0M | -41.1M | -38.8M | -30.5M | -23.5M | -13.3M | -13.9M | -16.2M | -21.4M |
| Income tax | 0 | 0 | -2.99M | 424.0K | 448.0K | 51.0K | 87.0K | 0 | 24.0K | 0 |
| Net income | -30.8M | -47.0M | -41.1M | -38.8M | -30.5M | -23.5M | -13.3M | -13.9M | -16.2M | -21.4M |
| Earnings per share, basic | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 | -0.38 | -0.49 | -0.76 |
| Earnings per share, diluted | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 | -0.38 | -0.49 | -0.76 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.7M | 15.1M | 25.7M | 18.6M | 39.6M | 27.1M | 47.5M | 8.25M | 3.05M | 15.4M |
| Short-term investments | 0 | 0 | ||||||||
| Inventory | 0 | 0 | ||||||||
| Current assets | 19.4M | 17.3M | 27.7M | 20.6M | 41.8M | 29.5M | 48.2M | 8.83M | 3.82M | 15.8M |
| Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 1.00K | ||||||||
| Total assets | 19.5M | 17.5M | 28.2M | 21.3M | 41.8M | 29.6M | 48.5M | 9.01M | 4.16M | 15.8M |
| Accounts payable | 3.25M | 5.66M | 6.43M | 3.89M | 1.80M | 1.29M | 1.66M | 297.0K | 608.0K | 910.0K |
| Current liabilities | 8.03M | 35.4M | 15.7M | 13.0M | 9.03M | 5.40M | 2.82M | 2.11M | 2.97M | 3.78M |
| Long-term debt | 133.7M | 85.1M | 71.7M | 39.8M | 29.0M | 0 | 0 | |||
| Total debt | 133.8M | 106.2M | 71.8M | 39.9M | 29.1M | 44.0K | 39.0K | |||
| Total liabilities | 145.7M | 120.6M | 88.4M | 53.5M | 39.2M | 5.41M | 2.87M | 2.11M | 2.97M | 3.78M |
| Shareholders' equity | -127.9M | -104.8M | -62.0M | -33.9M | 893.0K | 22.5M | 43.9M | 5.17M | -530.0K | 10.3M |
| Shares outstanding | 65.2M | 63.2M | 61.9M | 59.4M | 59.3M | 57.1M | 56.9M | 41.2M | 35.8M | 32.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.9M | -41.8M | -33.0M | -31.1M | -24.3M | -20.6M | -10.8M | -10.2M | -15.9M | -16.4M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -23.9M | -41.8M | -33.0M | -31.1M | -24.3M | -20.6M | -10.8M | -10.2M | -15.9M | -16.4M |
| Cash from investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash from financing | 26.5M | 31.2M | 40.0M | 10.0M | 36.8M | 263.0K | 50.1M | 15.4M | 3.58M | 5.92M |
| Dividends paid | -138.0K | -91.0K | -120.0K | -97.0K | -171.0K | -137.0K | -394.0K | -915.0K | -1.23M | -741.0K |
| Share buybacks | 667.0K | 845.0K | 671.0K | 899.0K | -30.0M | 263.0K | 50.5M | 15.4M | 696.0K | 5.92M |
| Change in cash | 2.60M | -10.5M | 7.07M | -21.1M | 12.5M | -20.3M | 39.2M | 5.20M | -12.3M | -10.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Oct 13, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Oct 13, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 13, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 2, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 4, 2026 | Financing | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 23, 2026 | Current report | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Apr 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 6, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 31, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 21, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Jan 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 31, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | Dec 23, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | Dec 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Oct 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Oct 22, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 22, 2025 | Meeting notice | SEC |
| 5 · Annual statement of ownership | Oct 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 9, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 16, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Jun 11, 2025 | Insider trade | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Current report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| 8-K · Current report | Feb 18, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 23, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 23, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | Dec 3, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Dec 3, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 3, 2024 | Meeting notice | SEC |
| 8-K · Current report | Nov 14, 2024 | Current report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 4, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 1, 2024 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Jul 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2024 | Insider trade | SEC |
| 5 · Annual statement of ownership | Apr 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 29, 2024 | Results | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Dec 7, 2023 | Current report | SEC |
| 5 · Annual statement of ownership | Dec 1, 2023 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Galectin Therapeutics Inc.’s releases · as of Nov 6, 2026
- Common shares
- 100,875,106
- Fully diluted
- 100,875,106
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 100,875,106 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 100,875,106 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Benjamin Carson Sr Other companies: Sinclair, Inc. (Director · Since at least Jun 11, 2024); Covenant Logistics Group, Inc. (Director · Since at least Jul 7, 2021); D.R. Horton, Inc. (Director · Since at least Apr 20, 2021); Vaccinogen Inc (Director · Aug 22, 2014 – Apr 20, 2015 · Past); Costco Wholesale Corporation (Director · Apr 27, 2006 – Feb 27, 2015 · Past) | Director · Since at least Dec 7, 2023 |
| Gilbert F. Amelio Other companies: 5BARz International Inc (Director · Nov 21, 2013 – Jul 8, 2014 · Past); InterDigital, Inc. (Director · Mar 1, 2011 – Apr 29, 2015 · Past); Jazz Technologies Inc (Chairman and CEO, Director · May 16, 2007 – Dec 17, 2007 · Past); AT&T Inc. (Director · Jan 31, 2006 – Apr 30, 2013 · Past) | Independent Director · Since at least Feb 12, 2009 |
| Sydney Colin Neill Other companies: Boston Therapeutics Inc (Director · Dec 3, 2013 – Feb 12, 2014 · Past); Pharmos Corp (President and CFO · Oct 5, 2006 – Jan 23, 2008 · Past); Raptor Pharmaceutical Corp (Chief Financial Officer · Aug 23, 2006 – Aug 23, 2006 · Past); GT Biopharma, Inc. (Director · Aug 1, 2006 – Nov 9, 2007 · Past) | Director · May 24, 2007 – Jun 28, 2011 · Past |
| Marc Rubin Other companies: Curis, Inc. (Director · Since at least Jun 3, 2010); Medicine Man Technologies Inc. (Director · Oct 28, 2022 – Oct 28, 2022 · Past); Titan Pharmaceuticals Inc (Executive Chairman, Director · Oct 1, 2007 – Jan 5, 2022 · Past) | Director · Oct 12, 2011 – Jan 23, 2025 · Past |
| Peter Traber Other companies: Cartesian Therapeutics, Inc. (Head of Research and Development · Since at least Aug 1, 2020); Lisata Therapeutics, Inc. (Director · Jan 22, 2015 – Jan 10, 2022 · Past); Tanox Inc (Director · Jun 2, 2006 – Jun 2, 2006 · Past) | President & CEO · Feb 12, 2009 – Jun 13, 2018 · Past |
| Dale H. Conaway Other companies: Bioxytran, Inc. (Director · Since at least Jul 1, 2020); Boston Therapeutics Inc (Director · Apr 4, 2014 – May 15, 2015 · Past) | Director · Mar 9, 2006 – Feb 8, 2009 · Past |
| Gilbert S. Omenn Other companies: Amesite Inc. (Director · Since at least Sep 25, 2020); Elicio Therapeutics, Inc. (Director · Feb 4, 2021 – Jun 9, 2022 · Past) | Director · Since at least Dec 14, 2017 |
| Pol F. Boudes Other companies: Protalix BioTherapeutics, Inc. (de) (Director · Since at least Jan 1, 2020); Amicus Therapeutics Inc (Chief Medical Officer · Jun 15, 2010 – Jun 4, 2012 · Past) | Chief Medical Officer · Mar 2, 2020 – Jan 24, 2024 · Past |
| Steven Prelack Other companies: Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 30, 2021 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jan 25, 2019 · Past) | Director · Mar 9, 2006 – Dec 15, 2016 · Past |
| Anthony Don Squeglia Other companies: Boston Therapeutics Inc (Chief Financial Officer · Dec 3, 2013 – Mar 10, 2015 · Past) | Chief Financial Officer · Oct 1, 2007 – Feb 2, 2010 · Past |
All 37 people
| Person | Seat |
|---|---|
| Carl Laurence Lueders Other companies: Micronetics Inc (Chief Financial Officer · Aug 18, 2008 – Aug 8, 2012 · Past) | Chief Financial Officer · Mar 9, 2006 – Mar 8, 2007 · Past |
| Henry Brem Other companies: Alseres Pharmaceuticals Inc (Director · Dec 6, 2007 – Jan 14, 2009 · Past) | Independent Director · Since at least Mar 12, 2026 |
| Jack W Callicutt Other companies: Vystar Corporation (Chief Financial Officer · Apr 12, 2010 – Mar 14, 2011 · Past) | Chief Financial Officer · Since at least Jul 1, 2013 |
| James C Czirr Other companies: Mitesco, Inc. (Director · Feb 7, 2017 – Feb 7, 2017 · Past) | Director · Jan 21, 2009 – Dec 1, 2023 · Past |
| Andrew Volosov | Vice President, Clinical Pharmacology and Pharmacokinetics · Since at least Nov 4, 2026 |
| Arthur Greenberg | Director · Aug 24, 2009 – Dec 15, 2016 · Past |
| Benjamin S. Carson | Independent Director · Since at least Nov 5, 2026 |
| Elissa J. Schwartz | Independent Director · Since at least Aug 31, 2020 |
| Harold Shlevin | Director · Since at least Jan 26, 2023 |
| Herman Paul Pressler | Director · May 26, 2011 – Mar 12, 2015 · Past |
| Jack W. Callicutt | Chief Financial Officer · Since at least Oct 6, 2026 |
| James Theophile Gourzis | Director · Feb 8, 2009 – Feb 8, 2009 · Past |
| Jerald K Rome | Director · Mar 7, 2013 – Mar 28, 2013 · Past |
| Jim Wilkins | Head of CMC and Pharmaceutical Development · Since at least Nov 4, 2026 |
| Joel Lewis | Chief Executive Officer (CEO) and President · Since at least Dec 14, 2017 |
| Kary Eldred | Director · Since at least May 22, 2018 |
| Kevin D. Freeman | Vice Chairman of the Board · Since at least May 26, 2011 |
| Khurram Jamil | Chief Medical Officer · Since at least Aug 1, 2024 |
| Maureen Foley | Chief Operating Officer · Mar 9, 2006 – Feb 2, 2010 · Past |
| Mildred S Christian | Director · Mar 9, 2006 – Feb 25, 2009 · Past |
| Richard A. Zordani | Independent Director · Since at least Nov 5, 2026 |
| Richard A Zordani Jr | Director · Since at least Jan 24, 2024 |
| Richard E. Uihlein | Director · Since at least Jan 24, 2024 |
| Rod D Martin | Director · Feb 12, 2009 – Mar 12, 2015 · Past |
| Sharisse Brutto | Vice President, Project Management · Since at least Nov 5, 2026 |
| Stephen Shulman | Director · Dec 14, 2017 – Jan 16, 2019 · Past |
| Theodore Daniel Zucconi | Director · Dec 14, 2017 – Apr 16, 2018 · Past |
Log in to ask 6ix AI your own questions about Galectin Therapeutics Inc.